Edgestream Partners, L.P. Reata Pharmaceuticals Inc Transaction History

Edgestream Partners, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$79.22 - $105.37 $687,550 - $914,506	-8,679 Reduced 70.28%	3,671 $374,000
Q1 2023 May 15, 2023	SELL	$30.85 - $93.17 $848,004 - $2.56 Million	-27,488 Reduced 69.0%	12,350 $1.12 Million
Q4 2022 Feb 13, 2023	SELL	$22.15 - $42.11 $928,572 - $1.77 Million	-41,922 Reduced 51.27%	39,838 $1.51 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $1.59 Million - $2.98 Million	81,760 New	81,760 $2.06 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

Stay updated on Edgestream Partners, L.P. with notifications on news.